Literature DB >> 18210043

[Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement].

C Trenkwalder1, S Boesch, A Ceballos-Baumann, D Dressler, K Eggert, T Gasser, H Honig, T Müller, H Reichmann, J P Sieb, A Storch, P Odin, W Poewe.   

Abstract

Intermittent subcutaneous apomorphine therapy should be considered in patients with advanced Parkinson's disease who experience recurrent off periods despite optimised oral treatment (according to guidelines), for reliable and quick reversal of these otherwise refractory periods. Such treatment is also called rescue therapy. At present, apomorphine injections with the apomorphine pen are underutilised, considering its current indications and contraindications. In the present consensus statement, concepts for the use of apomorphine are presented and discussed based on existing study results, indications, and contraindications. Recommendations for a practical approach are also provided.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18210043     DOI: 10.1007/s00115-007-2391-0

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  17 in total

1.  Continuous subcutaneous apomorphine as replacement for levodopa in severe parkinsonian patients after surgery.

Authors:  E Broussolle; M H Marion; P Pollak
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

Review 2.  [Apomorphine in the treatment of Parkinson's Disease].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

3.  A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.

Authors:  R B Dewey; J T Hutton; P A LeWitt; S A Factor
Journal:  Arch Neurol       Date:  2001-09

4.  Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.

Authors:  A J Hughes; S Bishop; B Kleedorfer; N Turjanski; W Fernandez; A J Lees; G M Stern
Journal:  Mov Disord       Date:  1993-04       Impact factor: 10.338

Review 5.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 6.  Apomorphine: an underutilized therapy for Parkinson's disease.

Authors:  W Poewe; G K Wenning
Journal:  Mov Disord       Date:  2000-09       Impact factor: 10.338

7.  Prophylactic iv ondansetron reduces nausea, vomiting and pruritus following epidural morphine for postoperative pain control.

Authors:  Jann-Inn Tzeng; Koung-Shing Chu; Shung-Tai Ho; Kuang-I Cheng; Kuo-Sheng Liu; Jhi-Joung Wang
Journal:  Can J Anaesth       Date:  2003-12       Impact factor: 5.063

8.  Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.

Authors:  L Ostergaard; L Werdelin; P Odin; O Lindvall; E Dupont; P B Christensen; E Boisen; N B Jensen; S H Ingwersen; M Schmiegelow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-06       Impact factor: 10.154

9.  Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.

Authors:  K Pietz; P Hagell; P Odin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154

10.  [Treatment of motor fluctuations in Parkinson's disease with subcutaneous injections of apomorphine].

Authors:  M Merello; R Leiguarda
Journal:  Medicina (B Aires)       Date:  1995       Impact factor: 0.653

View more
  1 in total

Review 1.  Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.

Authors:  Jie Dong; Yanhua Cui; Song Li; Weidong Le
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.